Publication Name	World Journal of Gastroenterology
Manuscript ID	5564
Country	Japan

Received	2013-09-15 21:10
Peer-Review Started	2013-09-15 22:49
To Make the First Decision	2013-10-29 12:39
Return for Revision	2013-10-31 10:25
Revised
Second Decision	2013-12-03 21:17
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2013-12-04 06:48
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-12-12 21:20
Publish the Manuscript Online	2014-01-20 16:41

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review
Manuscript Source	Invited Manuscript
All Author List	Shuang Wu, Tatsuo Kanda, Shingo Nakamoto, Fumio Imazeki and Osamu Yokosuka
Funding Agency and Grant Number	Funding Agency Grant Number Japan Society for Promotion of Science (JSPS) Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan Ministry of Health, Labour, and Welfare of Japan
Corresponding Author	Tatsuo Kanda, MD, PhD, Associate Professor, Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. kandat-cib@umin.ac.jp
Key Words	Direct-acting antiviral agent; Hepatitis C virus; Protease inhibitor; Resistance mutation; Sequence analysis
Core Tip	The standard of care for the treatment of hepatitis C virus (HCV) infection was peginterferon plus ribavirin until the recent approval of telaprevir- and boceprevir-containing combination therapies. These HCV protease inhibitors occasionally cause HCV variants with resistance mutations. We reviewed the literature reports of resistance variants of HCV protease inhibitors in treatment-na?ve patients with chronic HCV genotype 1, as well as our experience. Even in treatment-na?ve patients with chronic HCV genotype 1, naturally occurring HCV protease inhibitor-resistance mutations exist in some cases. The combination of direct-acting antiviral agents against regions other than HCV NS3/4A could eradicate HCV with these resistance variants.
Publish Date	2014-01-20 16:41
Citation	Wu S, Kanda T, Nakamoto S, Imazeki F, Yokosuka O. Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review. World J Gastroenterol 2013; 19(47): 8940-8948
URL	http://www.wjgnet.com/1007-9327/full/v19/i47/8940.htm
DOI	http://dx.doi.org/10.3748/wjg.v19.i47.8940

Full Article (PDF)	WJG-19-8940.pdf
Manuscript File	5564-Review.doc
Answering Reviewers	5564-Answering reviewers.pdf
Copyright License Agreement	5564-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	5564-Language certificate.pdf
Peer-review Report	5564-Peer review(s).pdf
Scientific Editor Work List	5564-Scientific editor work list.doc